Could a Two-Drug HIV pill work for transgender women?
NCT ID NCT06967753
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing whether switching to a two-drug HIV pill (dolutegravir plus lamivudine) can keep the virus under control in transgender women who are already on a stable three-drug regimen. About 50 participants will take the new pill once daily for 48 weeks. The main goal is to see if the virus stays suppressed, with a focus on safety and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dolutegravir and lamivudine (two-drug HIV pill)
What this could lead to
If successful, this could show that a simpler two-drug regimen works well for transgender women with HIV, potentially reducing side effects and pill burden.
What could go wrong
This is a small, early-phase study with only 50 participants and no comparison group, so results may not apply to everyone. There is a risk the simpler regimen may not keep the virus fully suppressed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital General de Agudos Dr. Juan A. Fernández, Infectious Diseases Division
RECRUITINGBuenos Aires, Buenos Aires F.D., 1425, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact